This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
McKesson (MCK) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
ABIOMED's (ABMD) international and U.S. Impella revenues improve in Q4.
Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.
Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.
Hologic (HOLX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.
Why You Should Hold AngioDynamics (ANGO) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Cardinal Health (CAH), HHS Partner to Offer Pandemic Support
by Zacks Equity Research
The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
Here's Why You Should Hold Masimo (MASI) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
What Makes The Cooper Companies (COO) a New Buy Stock
by Zacks Equity Research
The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.